By InvitationNot Applicable

Salivary Oxytocin as a Biomarker of Psychedelic Treatment

Switzerland80 participantsStarted 2026-01-05

Plain-language summary

This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>=18 years-old * MDD defined by DSM-V criteria, and resistant to treatment * Ongoing classical psychotherapeutic treatment * Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off). Exclusion Criteria: * Psychotic or bipolar disorder * High suicidal risk * Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders * Pregnancy or breastfeeding.

What they're measuring

Salivary Oxytocin

Timeframe: One day

Trial details

NCT IDNCT07345858

SponsorUniversity of Geneva, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07-31

View on ClinicalTrials.gov More Major Depressive Disorder (MDD) trials